Category Archives: BMY

Bristol-Myers Squibb Update

Posted on February 27, 2022 by Stephen Percoco

Raising 2022 Estimate and Adding 2023, Maintaining Outperform Rating and Price Target of $73 Bristol-Myers Squibb Company (BMS) achieved many operational milestones in 2021, advancing its development pipeline through clinical trials, new drug applications and regulatory approvals.  At its November … Continue reading →

Posted in BMY, Health Care | Tagged | Comments Off on Bristol-Myers Squibb Update

Bristol-Myers Squibb: Initiating Coverage

Posted on August 6, 2021 by Stephen Percoco

Initiating Coverage with an Outperform Rating. Prospects Beyond 2022 are Favorable. With the acquisitions of Celgene in 2019 and MyoKardia in 2020, BMS has substantially transformed its business and repositioned for growth.  Drugs added to the portfolio from the two … Continue reading →

Posted in BMY, Health Care | Tagged | Comments Off on Bristol-Myers Squibb: Initiating Coverage